SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

If you purchased or acquired Novo securities, and/or would like to discuss your legal rights and options please visit Novo Nordisk A/S Shareholder Class Action Lawsuit or contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com. According to the lawsuit, Defendants made misrepresentations concerning Novo's growth potential stemming from the Company's diabetes/obesity drug, GLP-1. If you wish to serve as lead plaintiff for the Class, you must file papers by September 30, 2025. A lead plaintif ...